<DOC>
	<DOCNO>NCT00000790</DOCNO>
	<brief_summary>PRIMARY : To evaluate effectiveness safety thalidomide treatment oral esophageal aphthous ulcer ( unrelated know infection malignancy ) patient advance HIV disease . To evaluate effect thalidomide HIV load patient population . Per 06/28/94 amendment , evaluate effectiveness thalidomide prevent recurrence patient whose aphthae completely heal end acute treatment . SECONDARY : To evaluate effect thalidomide blood tumor necrosis factor ( TNF ) level obtain pharmacokinetic data drug . Per 06/28/94 amendment , evaluate safety thalidomide . Per 05/10/95 amendment , explore substudy effect thalidomide idiopathic genital aphthous ulcer HIV-infected woman . Aphthous ulcer mouth esophagus interfere eat , result malnutrition wasting . Thalidomide propose effective therapy severe form aphthous ulceration AIDS patient .</brief_summary>
	<brief_title>Thalidomide Treatment Oral Esophageal Aphthous Ulcers HIV Viremia Patients With HIV Infection</brief_title>
	<detailed_description>Aphthous ulcer mouth esophagus interfere eat , result malnutrition wasting . Thalidomide propose effective therapy severe form aphthous ulceration AIDS patient . Patients randomize receive 4 week either thalidomide placebo orally , administer daily . Patients follow weekly . Complete responder 4 week acute treatment enter 24-week maintenance phase . A pharmacokinetic substudy include .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Viremia</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Stomatitis , Aphthous</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : AntiHIV therapy provide therapy remain constant 4 week prior study entry . Narcotic analgesia first week treatment ONLY IF patient experience somnolence . Patients must : Documented HIV infection AIDS . Biopsyconfirmed aphthous ulceration mouth esophagus last least 2 week . Negative culture ulcer Herpes simplex . En face diameter &gt; = 5 mm large aphthous ulcer . Life expectancy least 3 month . NOTE : This study approve prisoner participation . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Known allergy thalidomide . Grade 2 bad bilateral peripheral neuropathy . EXCLUDED FOR MAINTENANCE PHASE : Toxicity somnolence acute phase require discontinuation drug . Concurrent Medication : Excluded : Acute therapy opportunistic infection . ddC . Pentoxifylline . Methotrexate , trimetrexate , antineoplastic alkylating agent . Other putative immunomodulators . CNS depressant and/or medication sedative hypnotic effect . Systemic and/or oral topical corticosteroid . Systemic chemotherapy Kaposi 's sarcoma malignancy . Compounded antibacterial mouthwash contain antiinfective agent ( doxycycline , minocycline , tetracycline , nystatin ) . Concurrent Treatment : Excluded : Radiation head and/or neck . Patients follow prior condition exclude : History grade 2 bad bilateral peripheral neuropathy . Change antiHIV therapy within 4 week prior study entry . Prior enrollment ACTG 251 prior treatment aphthous ulcer thalidomide . Prior Medication : Excluded : Systemic and/or oral topical corticosteroid within 1 week prior first set blood draw . Other putative immunomodulators within 2 week prior study entry . Prior thalidomide aphthous ulcer .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Stomatitis , Aphthous</keyword>
</DOC>